



# Ulcerative Colitis Medicine Industry Research Report 2026

| Industry           | Published  | Pages      | Format |
|--------------------|------------|------------|--------|
| Service & Software | 2026-01-04 | 123        | PDF    |
| Single User        | Multi User | Enterprise |        |
| USD 2,950          | USD 4,430  | USD 5,900  |        |

## Description

The global Ulcerative Colitis Medicine market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Ulcerative Colitis Medicine market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Ulcerative Colitis Medicine market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Ulcerative Colitis Medicine market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Ulcerative Colitis Medicine include Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca and Cipla, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

## Report Scope

This report quantifies the global Ulcerative Colitis Medicine market in terms of revenue (US\$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Ulcerative Colitis Medicine.

## Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

- Ulcerative Colitis Medicine Market by Company
- Sumitomo
  - Pfizer
  - Novartis
  - Merck
  - Sanofi

Johnson and Johnson

GSK

AstraZeneca

Cipla

Sun Pharm

Allergan

Teva Pharmaceutical

Ulcerative Colitis Medicine Segment by Type

5-Aminosalicylic Acid

Corticosteroids

Immunomodulator Drugs

Biologics

Ulcerative Colitis Medicine Segment by Application

Ulcerative Proctitis

Proctosigmoiditis

Left-Sided Colitis

Pancolitis

Acute Severe Ulcerative Colitis

Ulcerative Colitis Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel  
United Arab Emirates  
Turkey  
Iran  
Egypt

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

### Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

### Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

### Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

### Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

### Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

### **Chapter 6:**

Detailed analysis of Ulcerative Colitis Medicine companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

### **Chapter 12:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

### **Chapter 13:**

The main points and conclusions of the report.

# Table of Contents

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Ulcerative Colitis Medicine by Type
  - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  - 2.2.2 5-Aminosalicylic Acid
  - 2.2.3 Corticosteroids
  - 2.2.4 Immunomodulator Drugs
  - 2.2.5 Biologics
- 2.3 Ulcerative Colitis Medicine by Application
  - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.3.2 Ulcerative Proctitis
  - 2.3.3 Proctosigmoiditis
  - 2.3.4 Left-Sided Colitis
  - 2.3.5 Pancolitis
  - 2.3.6 Acute Severe Ulcerative Colitis
- 2.4 Assumptions and Limitations

## 3 Ulcerative Colitis Medicine Breakdown Data by Type

- 3.1 Global Ulcerative Colitis Medicine Historic Market Size by Type (2021-2026)
- 3.2 Global Ulcerative Colitis Medicine Forecasted Market Size by Type (2027-2032)

## 4 Ulcerative Colitis Medicine Breakdown Data by Application

- 4.1 Global Ulcerative Colitis Medicine Historic Market Size by Application (2021-2026)
- 4.2 Global Ulcerative Colitis Medicine Forecasted Market Size by Application (2027-2032)

## 5 Global Growth Trends

- 5.1 Global Ulcerative Colitis Medicine Market Perspective (2021-2032)
- 5.2 Global Ulcerative Colitis Medicine Growth Trends by Region
  - 5.2.1 Global Ulcerative Colitis Medicine Market Size by Region: 2021 VS 2025 VS 2032
  - 5.2.2 Ulcerative Colitis Medicine Historic Market Size by Region (2021-2026)
  - 5.2.3 Ulcerative Colitis Medicine Forecasted Market Size by Region (2027-2032)
- 5.3 Ulcerative Colitis Medicine Market Dynamics
  - 5.3.1 Ulcerative Colitis Medicine Industry Trends
  - 5.3.2 Ulcerative Colitis Medicine Market Drivers
  - 5.3.3 Ulcerative Colitis Medicine Market Challenges
  - 5.3.4 Ulcerative Colitis Medicine Market Restraints

## 6 Market Competitive Landscape by Players

- 6.1 Global Top Ulcerative Colitis Medicine Players by Revenue
    - 6.1.1 Global Top Ulcerative Colitis Medicine Players by Revenue (2021-2026)
    - 6.1.2 Global Ulcerative Colitis Medicine Revenue Market Share by Players (2021-2026)
  - 6.2 Global Ulcerative Colitis Medicine Industry Players Ranking, 2023 VS 2024 VS 2025
  - 6.3 Global Key Players of Ulcerative Colitis Medicine Head Office and Area Served
  - 6.4 Global Ulcerative Colitis Medicine Players, Product Type & Application
  - 6.5 Global Ulcerative Colitis Medicine Manufacturers Established Date
  - 6.6 Global Ulcerative Colitis Medicine Market CR5 and HHI
  - 6.7 Global Players Mergers & Acquisition
- 

7 North America

- 7.1 North America Ulcerative Colitis Medicine Market Size (2021-2032)
  - 7.2 North America Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 7.3 North America Ulcerative Colitis Medicine Market Size by Country (2021-2026)
  - 7.4 North America Ulcerative Colitis Medicine Market Size by Country (2027-2032)
  - 7.5 United States
    - 7.5 United States
  - 7.6 Canada
  - 7.7 Mexico
- 

8 Europe

- 8.1 Europe Ulcerative Colitis Medicine Market Size (2021-2032)
  - 8.2 Europe Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 8.3 Europe Ulcerative Colitis Medicine Market Size by Country (2021-2026)
  - 8.4 Europe Ulcerative Colitis Medicine Market Size by Country (2027-2032)
  - 8.5 Germany
  - 8.6 France
  - 8.7 U.K.
  - 8.8 Italy
  - 8.9 Spain
  - 8.10 Russia
  - 8.11 Netherlands
  - 8.12 Nordic Countries
- 

9 Asia-Pacific

- 9.1 Asia-Pacific Ulcerative Colitis Medicine Market Size (2021-2032)
  - 9.2 Asia-Pacific Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 9.3 Asia-Pacific Ulcerative Colitis Medicine Market Size by Country (2021-2026)
  - 9.4 Asia-Pacific Ulcerative Colitis Medicine Market Size by Country (2027-2032)
  - 9.5 China
  - 9.6 Japan
  - 9.7 South Korea
  - 9.8 India
  - 9.9 Australia
  - 9.10 China Taiwan
  - 9.11 Southeast Asia
- 

10 South America

- 10.1 South America Ulcerative Colitis Medicine Market Size (2021-2032)
- 10.2 South America Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Ulcerative Colitis Medicine Market Size by Country (2021-2026)

- 10.4 South America Ulcerative Colitis Medicine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru

## 11 Middle East & Africa

- 11.1 Middle East & Africa Ulcerative Colitis Medicine Market Size (2021-2032)
- 11.2 Middle East & Africa Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Ulcerative Colitis Medicine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Ulcerative Colitis Medicine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt

## 12 Players Profiled

- 12.1 Sumitomo
  - 12.1.1 Sumitomo Company Information
  - 12.1.2 Sumitomo Business Overview
  - 12.1.3 Sumitomo Revenue in Ulcerative Colitis Medicine Business (2021-2026)
  - 12.1.4 Sumitomo Ulcerative Colitis Medicine Product Portfolio
  - 12.1.5 Sumitomo Recent Developments
- 12.2 Pfizer
  - 12.2.1 Pfizer Company Information
  - 12.2.2 Pfizer Business Overview
  - 12.2.3 Pfizer Revenue in Ulcerative Colitis Medicine Business (2021-2026)
  - 12.2.4 Pfizer Ulcerative Colitis Medicine Product Portfolio
  - 12.2.5 Pfizer Recent Developments
- 12.3 Novartis
  - 12.3.1 Novartis Company Information
  - 12.3.2 Novartis Business Overview
  - 12.3.3 Novartis Revenue in Ulcerative Colitis Medicine Business (2021-2026)
  - 12.3.4 Novartis Ulcerative Colitis Medicine Product Portfolio
  - 12.3.5 Novartis Recent Developments
- 12.4 Merck
  - 12.4.1 Merck Company Information
  - 12.4.2 Merck Business Overview
  - 12.4.3 Merck Revenue in Ulcerative Colitis Medicine Business (2021-2026)
  - 12.4.4 Merck Ulcerative Colitis Medicine Product Portfolio
  - 12.4.5 Merck Recent Developments
- 12.5 Sanofi
  - 12.5.1 Sanofi Company Information
  - 12.5.2 Sanofi Business Overview
  - 12.5.3 Sanofi Revenue in Ulcerative Colitis Medicine Business (2021-2026)
  - 12.5.4 Sanofi Ulcerative Colitis Medicine Product Portfolio

12.5.5 Sanofi Recent Developments

12.6 Johnson and Johnson

12.6.1 Johnson and Johnson Company Information

12.6.2 Johnson and Johnson Business Overview

12.6.3 Johnson and Johnson Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.6.4 Johnson and Johnson Ulcerative Colitis Medicine Product Portfolio

12.6.5 Johnson and Johnson Recent Developments

12.7 GSK

12.7.1 GSK Company Information

12.7.2 GSK Business Overview

12.7.3 GSK Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.7.4 GSK Ulcerative Colitis Medicine Product Portfolio

12.7.5 GSK Recent Developments

12.8 AstraZeneca

12.8.1 AstraZeneca Company Information

12.8.2 AstraZeneca Business Overview

12.8.3 AstraZeneca Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.8.4 AstraZeneca Ulcerative Colitis Medicine Product Portfolio

12.8.5 AstraZeneca Recent Developments

12.9 Cipla

12.9.1 Cipla Company Information

12.9.2 Cipla Business Overview

12.9.3 Cipla Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.9.4 Cipla Ulcerative Colitis Medicine Product Portfolio

12.9.5 Cipla Recent Developments

12.10 Sun Pharm

12.10.1 Sun Pharm Company Information

12.10.2 Sun Pharm Business Overview

12.10.3 Sun Pharm Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.10.4 Sun Pharm Ulcerative Colitis Medicine Product Portfolio

12.10.5 Sun Pharm Recent Developments

12.11 Allergan

12.11.1 Allergan Company Information

12.11.2 Allergan Business Overview

12.11.3 Allergan Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.11.4 Allergan Ulcerative Colitis Medicine Product Portfolio

12.11.5 Allergan Recent Developments

12.12 Teva Pharmaceutical

12.12.1 Teva Pharmaceutical Company Information

12.12.2 Teva Pharmaceutical Business Overview

12.12.3 Teva Pharmaceutical Revenue in Ulcerative Colitis Medicine Business (2021-2026)

12.12.4 Teva Pharmaceutical Ulcerative Colitis Medicine Product Portfolio

12.12.5 Teva Pharmaceutical Recent Developments

---

13 Report Conclusion

---

14 Disclaimer

# List of Tables and Figures

## List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Ulcerative Colitis Medicine Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Ulcerative Colitis Medicine Revenue Market Share by Type (2021-2026)
- Table 7: Global Ulcerative Colitis Medicine Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Ulcerative Colitis Medicine Revenue Market Share by Type (2027-2032)
- Table 9: Global Ulcerative Colitis Medicine Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Ulcerative Colitis Medicine Revenue Market Share by Application (2021-2026)
- Table 11: Global Ulcerative Colitis Medicine Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Ulcerative Colitis Medicine Revenue Market Share by Application (2027-2032)
- Table 13: Global Ulcerative Colitis Medicine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Ulcerative Colitis Medicine Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Ulcerative Colitis Medicine Market Share by Region (2021-2026)
- Table 16: Global Ulcerative Colitis Medicine Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Ulcerative Colitis Medicine Market Share by Region (2027-2032)
- Table 18: Ulcerative Colitis Medicine Industry Trends
- Table 19: Ulcerative Colitis Medicine Industry Drivers
- Table 20: Ulcerative Colitis Medicine Industry Opportunities and Challenges
- Table 21: Ulcerative Colitis Medicine Market Restraints
- Table 22: Global Top Ulcerative Colitis Medicine Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Ulcerative Colitis Medicine Revenue Market Share by Players (2021-2026)
- Table 24: Global Ulcerative Colitis Medicine Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Ulcerative Colitis Medicine, Headquarters and Area Served
- Table 26: Global Ulcerative Colitis Medicine Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Ulcerative Colitis Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Ulcerative Colitis Medicine Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Ulcerative Colitis Medicine Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Ulcerative Colitis Medicine Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Ulcerative Colitis Medicine Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Ulcerative Colitis Medicine Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Ulcerative Colitis Medicine Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Ulcerative Colitis Medicine Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Ulcerative Colitis Medicine Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Ulcerative Colitis Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Ulcerative Colitis Medicine Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Ulcerative Colitis Medicine Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Sumitomo Company Information
- Table 46: Sumitomo Business Overview
- Table 47: Sumitomo Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 48: Sumitomo Ulcerative Colitis Medicine Product Portfolio
- Table 49: Sumitomo Recent Developments
- Table 50: Pfizer Company Information
- Table 51: Pfizer Business Overview
- Table 52: Pfizer Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 53: Pfizer Ulcerative Colitis Medicine Product Portfolio
- Table 54: Pfizer Recent Developments

- Table 55: Novartis Company Information
- Table 56: Novartis Business Overview
- Table 57: Novartis Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 58: Novartis Ulcerative Colitis Medicine Product Portfolio
- Table 59: Novartis Recent Developments
- Table 60: Merck Company Information
- Table 61: Merck Business Overview
- Table 62: Merck Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 63: Merck Ulcerative Colitis Medicine Product Portfolio
- Table 64: Merck Recent Developments
- Table 65: Sanofi Company Information
- Table 66: Sanofi Business Overview
- Table 67: Sanofi Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 68: Sanofi Ulcerative Colitis Medicine Product Portfolio
- Table 69: Sanofi Recent Developments
- Table 70: Johnson and Johnson Company Information
- Table 71: Johnson and Johnson Business Overview
- Table 72: Johnson and Johnson Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 73: Johnson and Johnson Ulcerative Colitis Medicine Product Portfolio
- Table 74: Johnson and Johnson Recent Developments
- Table 75: GSK Company Information
- Table 76: GSK Business Overview
- Table 77: GSK Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 78: GSK Ulcerative Colitis Medicine Product Portfolio
- Table 79: GSK Recent Developments
- Table 80: AstraZeneca Company Information
- Table 81: AstraZeneca Business Overview
- Table 82: AstraZeneca Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 83: AstraZeneca Ulcerative Colitis Medicine Product Portfolio
- Table 84: AstraZeneca Recent Developments
- Table 85: Cipla Company Information
- Table 86: Cipla Business Overview
- Table 87: Cipla Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 88: Cipla Ulcerative Colitis Medicine Product Portfolio
- Table 89: Cipla Recent Developments
- Table 90: Sun Pharm Company Information
- Table 91: Sun Pharm Business Overview
- Table 92: Sun Pharm Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 93: Sun Pharm Ulcerative Colitis Medicine Product Portfolio
- Table 94: Sun Pharm Recent Developments
- Table 95: Allergan Company Information
- Table 96: Allergan Business Overview
- Table 97: Allergan Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 98: Allergan Ulcerative Colitis Medicine Product Portfolio
- Table 99: Allergan Recent Developments
- Table 100: Teva Pharmaceutical Company Information
- Table 101: Teva Pharmaceutical Business Overview
- Table 102: Teva Pharmaceutical Revenue in Ulcerative Colitis Medicine Business (2021-2026) & (US\$ Million)
- Table 103: Teva Pharmaceutical Ulcerative Colitis Medicine Product Portfolio
- Table 104: Teva Pharmaceutical Recent Developments
- Table 105: Authors List of This Report

**List of Figures:**

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Ulcerative Colitis Medicine Product Image
- Figure 5: Global Ulcerative Colitis Medicine Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Ulcerative Colitis Medicine Market Share by Type: 2025 VS 2032
- Figure 7: 5-Aminosalicylic Acid Product
- Figure 8: Corticosteroids Product
- Figure 9: Immunomodulator Drugs Product
- Figure 10: Biologics Product

- Figure 11: Global Ulcerative Colitis Medicine Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 12: Global Ulcerative Colitis Medicine Market Share by Application: 2025 VS 2032
- Figure 13: Ulcerative Proctitis Product
- Figure 14: Proctosigmoiditis Product
- Figure 15: Left-Sided Colitis Product
- Figure 16: Pancolitis Product
- Figure 17: Acute Severe Ulcerative Colitis Product
- Figure 18: Global Ulcerative Colitis Medicine Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 19: Global Ulcerative Colitis Medicine Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 20: Global Ulcerative Colitis Medicine Market Share by Region: 2025 VS 2032
- Figure 21: Global Ulcerative Colitis Medicine Market Share by Players in 2025
- Figure 22: Global Ulcerative Colitis Medicine Manufacturers Established Date
- Figure 23: Global Top 5 and 10 Ulcerative Colitis Medicine Players Market Share by Revenue in 2025
- Figure 24: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 25: North America Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: North America Ulcerative Colitis Medicine Market Share by Country (2021-2032)
- Figure 27: United States Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 28: Canada Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Mexico Ulcerative Colitis Medicine Market Share by Country (2021-2032)
- Figure 30: Europe Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: Europe Ulcerative Colitis Medicine Market Share by Country (2021-2032)
- Figure 32: Germany Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: France Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: U.K. Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Italy Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Spain Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Russia Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Netherlands Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Nordic Countries Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Asia-Pacific Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Asia-Pacific Ulcerative Colitis Medicine Market Share by Country (2021-2032)
- Figure 42: China Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: Japan Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: South Korea Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: India Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: India Ulcerative Colitis Medicine Market Share by Country (2021-2032)
- Figure 47: Australia Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: China Taiwan Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: Southeast Asia Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: South America Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: South America Ulcerative Colitis Medicine Market Share by Country (2021-2032)
- Figure 52: Brazil Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Argentina Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Chile Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Colombia Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 56: Peru Ulcerative Colitis Medicine Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 57: Sumitomo Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 58: Pfizer Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 59: Novartis Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 60: Merck Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 61: Sanofi Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 62: Johnson and Johnson Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 63: GSK Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 64: AstraZeneca Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 65: Cipla Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 66: Sun Pharm Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 67: Allergan Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)
- Figure 68: Teva Pharmaceutical Revenue Growth Rate in Ulcerative Colitis Medicine Business (2021-2026)